(Q37858534)

24 August 2017

1 reference

title

Angiogenesis-related molecular targets in esophageal cancer (English)

1 reference

24 August 2017

1 reference

Liu Hong

1

1 reference

24 August 2017

Shujun Li

2

1 reference

24 August 2017

Yu Han

3

1 reference

24 August 2017

Jianjun Du

4

1 reference

24 August 2017

Hongwei Zhang

5

1 reference

24 August 2017

Jipeng Li

6

1 reference

24 August 2017

Qingchuan Zhao

7

1 reference

24 August 2017

Kaichun Wu

8

1 reference

24 August 2017

Daiming Fan

9

1 reference

24 August 2017

language of work or name

English

0 references

publication date

28 March 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

637-644

1 reference

Secondary prevention of esophageal squamous cell carcinoma in areas where smoking, alcohol, and betel quid chewing are prevalent

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Esophageal adenocarcinoma arising in Barrett esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Clinical Application of Therapies Targeting VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Novel targets in esophageal and gastric cancer: beyond antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Anti-angiogenic therapy: adapting strategies to overcome resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Imaged-based high-throughput screening for anti-angiogenic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Anti-VEGF therapy for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Black sheep of the VEGF family gives hope for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Esophageal ulcer in a patient who received bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

New molecular targeted therapies integrated with radiation therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Deciphering the anticancer mechanisms of sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Cellular responses to EGFR inhibitors and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Gefitinib for the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

EGFR pathway in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

A report from the 46th Annual Meeting of the American Society of Clinical Oncology (June 4-8, 2010 - Chicago, Illinois, USA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.571203

10.1517/13543784.2011.571203

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference